In our work, neither the age (using an arbitrary cutoff of 75 years old) changed acromegaly clinical presentation in terms of tumor size or GH/IGF-1 circulating concentrations, nor was the overall response to treatment different at very advanced ages. This evidence concerns the gene GH1 and neoplasm.